[Top] [All Lists]

[e-drug] Summer courses in Utrecht, The Netherlands

E-DRUG: Summer courses in Utrecht, The Netherlands
Dear E-Druggers,

This summer, the Division of Pharmacoepidemiology and Clinical Pharmacology at 
Utrecht University, the Netherlands, offers you again three challenging 
international summer courses:

25-29 June 2012 - Pharmacoepidemiology & Drug safety

2-6 July 2012 - Pharmaceutical Policy Analysis (in collaboration with WHO)

9-13 July 2012 - Pharmacoeconomics

More detailed information can be found below or on the summer school website 
(www.utrechtsummerschool.nl). All courses will cover the key issues in each 
field and focus on the most important research methods used. All course 
teachers have extensive expertise in their field.

A few scholarships are available for the Pharmaceutical Policy Analysis course. 
These scholarships include course fee, basic student housing as described on 
the summer school website and a small daily allowance to cover expenses for 
food and local transport. International travel is at the expense of the 
applicant or his/her institution. If you wish to apply for a scholarship, 
please do so before 15 April by sending an application letter including 
motivation plus CV to Aukje Mantel (a.k.mantel@uu.nl). All applicants will be 
notified by 1 May 2012.

Supplementary, there is a cultural and social programme arranged for you to 
make sure that you experience the best of Utrecht. We look forward to welcoming 
you in Utrecht!

Warm wishes,

Aukje Mantel

M7 Pharmaceutical Policy Analysis (2-6 July 2012)

Medicines are among the most regulated products in society. From the earliest 
pre-clinical stages onward, policy makers want to foster the development of 
safe, effective and affordable medicines for patients in need of 
pharmacotherapy. When a drug reaches the market, it is the beginning of a 
process of complex interactions between patients, prescribers, insurers, 
pharmaceutical companies and governments. Furthermore, the inequity in access 
to medicines is still a defining characteristic of the global pharmaceutical 
market place.

The aim of the course is to give students insight into current developments in 
pharmaceutical policy making as well to give a better understanding of the 
methods available for analysing the effects of policy interventions. As a 
collaborator on this course, the World Health Organization will provide faculty 
for several of the sessions.

You will experience an intensive programme covering the following topics:

Pharmaceutical Policy Analysis issues and methods; current challenges in drug 
innovation; access, affordability and reimbursement systems; regulatory issues 
and challenges; policy and politics; synthesis, case studies & public health

Course directors: Prof. Dr. Bert Leufkens, Dr. Richard Laing (World Health 
Organization) and Dr. Aukje Mantel.

M8 Pharmacoepidemiology & Drug Safety (25-29 June 2012)

With the prospect that innovative drug therapies will be introduced in the 
coming years, society demands new approaches and concepts for comparative 
risk/benefit evaluation. Assessment of safety and risk management of different 
drug therapies is done in the framework of observational epidemiological 
studies (proof of ‘safety’, proof of ‘effectiveness’). This is the logical next 
step after randomized clinical trials, which are designed to provide evidence 
of a drugs ‘efficacy’.

The course will cover key issues in pharmacoepidemiologic and drug safety 

Special topics include databases and molecular pharmacoepidemiology. Students 
will learn about the typical problems (e.g. confounding by indication, rare 
side effects) and approaches to deal with these problems in the practice of 

You will experience an intensive programme covering the following topics:

Study Design and Methods; Confounding and other biases; Methods in drug safety 
research; Drug Safety and Risk Management; Overview of Pharmacoepidemiological 
databases; Molecular Pharmacoepidemiology; Drug utilization research; 
Synthesis, case studies & public health

Course directors: Dr. O.H. Klungel and Dr. T.P. van Staa
Lecturers: Prof. S. Suissa, Prof. H.G.M. Leufkens, Prof. A. de Boer, Prof. 
A.C.G Egberts, Dr. O.H. Klungel, Dr. T.P. van Staa, Dr. F. de Vries

M14 Pharmacoeconomics (9-13 July 2012)

Today's society is confronted with ever increasing health care costs. One of 
the factors is the cost of drug innovations. Diseases waiting for therapeutic 
solutions are complicated and multifactorial in nature. As a result, drug 
innovation has become even more complex leading to high tech and therefore high 
cost solutions. The question arises, what is the added value of such high cost 
innovations and how can it be determined when both benefit and harm are 
considered. Health economics, and more specific pharmacoeconomics, aims to 
provide a neutral scientific approach to this challenge.

This course aims to provide a broad perspective of the field, including a 
variety of subjects from views of the different stakeholders to more in depth 
methodological approaches, illustrated with examples and exercises.

You will experience an intensive programme covering the following topics:

Pharmacoeconomic techniques; Study designs and methods; Critical appraisal of 
pharmacoeconomic studies; The (im)possibilities of the use of HTA and 
pharmacoeconomics in regulatory decisions; The economics of personalized 
medicine; Pharmacoeconomics of orphan drugs

Course directors: Dr. A.H. Maitland-van der Zee and Dr. A. Hovels
Lecturers: Prof. J. Raaijmakers, Prof D. Veenstra, Dr. A.H. Maitland-van der 
Zee and Dr. A. Hovels, and others

General information for all courses

Target groups

(Post)graduates and professionals within governments, NGOs, industry, 
universities with a basic knowledge public health/medicine who have an interest 
in the policy aspects of pharmaceuticals, pharmacoepidemiology and/or 

Fee and combinations

€900,- per course (including course materials + lunches + course dinner, 
excluding housing). Combination fee for two courses is €1400,- (excluding 
housing), combination fee for all three courses combined is €1800,- (excluding 

Deadline for application

31 May 2012, see www.utrechtsummerschool.nl (information summer school and 
course registration)

Aukje Mantel-Teeuwisse, PhD
Managing director WHO Collaborating Centre for Pharmacoepidemiology & 
Pharmaceutical Policy Analysis 
Utrecht Institute for Pharmaceutical Sciences | Division Pharmacoepidemiology & 
Clinical Pharmacology |
PO Box 80 082 | 3508 TB Utrecht | The Netherlands | Tel: +31 6 22736017 or +31 
30 253 7324 (secretariat)

Visiting address:
David de Wied building | Universiteitsweg 99 | 3584 CG Utrecht | the Netherlands

<Prev in Thread] Current Thread [Next in Thread>
  • [e-drug] Summer courses in Utrecht, The Netherlands, Mantel-Teeuwisse, A.K. (Aukje) <=